Sign up USA
Proactive Investors - Run By Investors For Investors

CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Cancerous cells
CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade

CytomX Therapeutics Inc (NASDAQ:CTMX) saw its shares shoot almost 25% higher in early New York trading after the biotech firm said it would receive a US$200mln upfront payment from drugs giant Bristol-Myers Squibb Co. (NYSE:BMY).

The payment is part of the expansion of a collaboration pact to discover cancer treatments using CytomX's Probody platform.

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.

Bristol-Myers’ head of discovery, Carl Decicco, said: “CytomX's Probody platform has enhanced our discovery research as we seek to direct the therapeutic effects of immunotherapy in a more targeted approach against tumor.”

CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade.



Register here to be notified of future CTMX Company articles

Related Articles

eye-766166_1280_583251a48f148.jpg
November 20 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Netscientific has its thumbs in a few clinical pies
March 31 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use